Navigation Links
New once-a-week treatment for type 2 diabetes developed by Mount Sinai researcher
Date:9/7/2008

(Toronto, ON, September 8, 2008) In a study published by the Lancet journal today, Toronto researcher Dr. Daniel Drucker reported that a new once-weekly treatment for type 2 diabetes could replace the more common twice-daily injection.

"Over two million Canadians have diabetes," said Dr. Daniel Drucker, clinician-scientist and Senior Investigator at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital. "There is currently no available therapy for type 2 diabetes that patients can receive once a week."

The new treatment, Exenatide once weekly is the first in a new class of long-acting medications that mimic the action of GLP-1 (glucagon-like peptide), a naturally occurring hormone that is produced in the gut after eating. The report compared outcomes for patients self-injecting Exenatide once weekly against results from the conventional 14 injections a week, as in the currently available version of the drug known as Exenatide (Byetta).

In an international multicentre 6-month clinical trial involving 300 eligible patients, 75 per cent of study subjects who received the once-weekly Exenatide got their diabetes under control as defined by reaching target glucose levels. Patients treated with Exenatide once weekly also experienced fewer side effects, had no increased risk of hypoglycemia (decrease in blood sugars) and saw reductions in body weight.

Dr. Drucker has studied the gut hormone GLP-1 for over 20 years. Multiple drugs based on GLP-1 action are under active clinical development, and the new once-weekly treatment is expected to undergo Canadian regulatory review as early as 2009.

"Biomedical research reaches patients and improves lives," said Dr. Jim Woodgett, Director of Research at the Samuel Lunenfeld Research Institute. "Dr. Drucker is a world-expert in the development of peptide hormone-based therapies for the treatment of human disease and this is an excellent example of moving discovery
'/>"/>

Contact: Nikki Luscombe
luscombe@lunenfeld.ca
416-586-4800 x2046
Samuel Lunenfeld Research Institute
Source:Eurekalert

Page: 1 2

Related biology news :

1. Landmark study opens door to new cancer, aging treatments
2. Common treatment to delay labor decreases preterm infants risk for cerebral palsy
3. UC Davis researchers define characteristics, treatment options for XXYY syndrome
4. Why a common treatment for prostate cancer ultimately fails
5. Biodegradable polymers show promise for improving treatment of acute inflammatory diseases
6. Childrens national co-leads nationwide study of landmark sickle cell treatment
7. Potatoes may hold key to Alzheimers treatment
8. Blood pressure response to daily stress provides clues for better hypertension treatment
9. Genes newly explained effect on height may change tumor disorder treatment
10. Songbirds may hold key to advances in treatment of brain degeneration
11. Treatment corrects severe insulin imbalance in animal studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... of Tbingen, Arizona State University, the Wellcome Trust Sanger ... (Swiss TPH) isolated Mycobacterium pinnipedii from skeletons ... old. The pathogen is a relative of the TB ... in humans today. These researchers assume that seals carried ... link to sea lions was unexpected" comments Sebastien Gagneux, ...
(Date:8/20/2014)... Using population-based screening outcomes of approximately 3 million ... four researchers at the University of Massachusetts Medical School, ... (SCID) can be successfully implemented across public health newborn ... in the Aug. 20 issue of the Journal ... showed the rate of SCID in newborns is higher ...
(Date:8/20/2014)... Institutes of Health has awarded the Oklahoma Medical Research ... research on anthrax and the bacteria,s effects on humans. ... Ph.D., and his colleagues have studied the human immune ... Centers for Human Immunology. The original funding came soon ... the heels of the terrorist attacks of Sept. 11, ...
Breaking Biology News(10 mins):Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3$14.5 million grant awarded to continue anthrax studies 2
... Zeneca have found a new way to use solid-state NMR ... spot unwanted polymorphs in pharmaceuticals. Pharmaceuticals companies are constantly ... can actually exist in more than one form or crystal ... different ways. Now researchers at the University of Warwick and ...
... AMES, Iowa -- Forests in the nation,s Upper Midwest ... settlers. And more changes may be coming. That,s ... professor in Iowa State University,s department of Natural Resource ... "There,s been a shift in the entire ecosystem," said ...
... TRADED BROKERAGE TO UTILIZE TITANIUM,S ... SECURITY SOLUTIONS, ... Board: TTNUF), a leading biometric and security solutions,provider announced today that ... 600837). Titanium will install its,Biometrics Access Control System in Haitong,s newly ...
Cached Biology News:NMR researchers unlock hydrogen's secrets to spot polymorphism in pharmaceuticals 2Upper Midwest forests are losing diversity, complexity, ISU study finds 2Titanium Group Announces Contract With Haitong Securities 2Titanium Group Announces Contract With Haitong Securities 3Titanium Group Announces Contract With Haitong Securities 4
(Date:8/21/2014)... 21, 2014 OTC Markets Group ... a biotechnology company, on its approval to list ... on OTCQX®, the best marketplace for established U.S. ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... execution of its growth strategy and achievement of ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Pursuit ... selling optimization technology and services for Life Sciences ... “Grading Pharma’s Use of New Commercial Sales Models” ... & Analytics. , The article examines some innovative ... that are being tested in the pharmaceutical market. ...
(Date:8/21/2014)... SoundConnect , a unified communication ... of the nation’s Fastest Growing Private Companies by ... consecutive year. Inc. magazine today ranked SoundConnect NO. ... exclusive ranking of the nation's fastest-growing private companies. ... the most important segment of the economy—America’s independent ...
(Date:8/20/2014)... patented university inventions licensed to biotechnology firms has ... To open these roadblocks, the researchers suggest that ... discovery stage could lead to faster commercialization down ... from discoveries made in university laboratories and licensed ... clinical trials, which have a high failure rate. ...
Breaking Biology Technology:OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3
... it plans to buy its former parent AT&T , ... opportunities. , ,Drew Petersen, director of legislative affairs for ... is a sign that SBC plans to become a global ... Petersen said tries to present itself as a Midwestern company, ...
... Depressed? , ,Considering we just escaped January a ... the cold, dark and dank weather thats no ... 24 (just one week ago) was the most depressing ... bear an extra psychological burden because of the challenges ...
... biotech company moving to Madison from Chicago is being ... state. , ,Governor Jim Doyle announced earlier this week ... from the Department of Commerce Technology Venture Fund ... programs to help the company purchase new equipment and ...
Cached Biology Technology:SBC merger with AT&T could open opportunities in Wisconsin 2Post-January, tech entrepreneurs have reasons to be depressed 2Post-January, tech entrepreneurs have reasons to be depressed 3Post-January, tech entrepreneurs have reasons to be depressed 4
... The kit contains 5 ml CELLection Dynabeads ... against the human epithelial antigen EpCAM and ... 5 log enrichment of epithelial tumour cells ... Tumour cells clumps can be enriched from ...
Recombinant Human CCL21/6Ckine (Mucin Stalk Chimera)...
Recombinant Human Erythropoietin (Tissue Culture Grade)...
Acrylamide PAGE 40% Solution, 1 l. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Gel Casting Chemicals....
Biology Products: